S-32 PG 242 Short Stem

计划入组 45 人 · 首次发布于 2021 年 10 月 19 日

TAK-242 in Patients With Acute Alcoholic Hepatitis

计划入组 100 人 · 首次发布于 2020 年 11 月 6 日

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

计划入组 403 人 · 首次发布于 2024 年 2 月 6 日

FMC-376

FMC-2

FMC-220

FMC Corporation

United States

FMC RENALCARE CORP.

Philippines

Fresenius Medical Care De Mexico, S.A. De C.V.

Mexico

Frontier Medicines Unveils FMC-242, Novel PI3Kα/RAS Inhibitor Targeting Cancer's Most Common Genetic Drivers

Frontier Medicines Appoints Former Seagen CEO David Epstein to Board as Company Advances Covalent Precision Medicine Pipeline

Frontier Medicines Presents Breakthrough Data on FMC-220, First-in-Class p53 Y220C Activator for Cancer Treatment